Sentinel For Biosimilars? Biologics Post-Market Monitoring Is Focus Of New Consortium

Group of sponsors, insurers and health systems will draw on datasets of de-identified pharmacy and medical claims data to monitor effectiveness and safety of novel biologics and their corresponding biosimilars.